Mayne Pharma has purchased 37 approved and 5 FDA filed products from Teva and Allergan for $652 million. The deal transforms the scope and breadth of Mayne Pharma’s U.S. generics division and is expected to propel the company into the top 25 retail generic pharmaceutical companies and the top 2 in the generic oral contraceptives market in the U.S. The acquisition increases and diversifies Mayne Pharma’s earnings across more products, therapeutic areas, dosage forms and complex technologies...